CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 130 target
Drug / intervention
SRT +1 moreradiation
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Age 18 years or older
  • ✓At least one brain metastasis from large cell cancer suitable for SRT
  • ✓Karnofsky Performance Status of 70 or higher
  • ✓Able to provide written informed consent
Key exclusion· 5
  • ✕MRI contraindication
  • ✕Primary tumor of small cell lung cancer, germinoma, or lymphoma
  • ✕Prior whole brain radiotherapy or SRT to current target brain metastases (in-field re-irradiation)
  • ✕Presence of leptomeningeal metastases

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05346367
NCT05346367N/ARecruitingOn TrackUpdated 27mo ago
Long Recruiting
CompareCT.gov

Improving Therapeutic Ratio With Hypo Fractionated Stereotactic Radiotherapy for Brain Metastases

Haaglanden Medical Centre·interventional·Posted Apr 26, 2022·Updated Mar 12, 2024

In Brief

A clinical study evaluating SRT and fSRT for Brain Metastases. Currently recruiting, targeting 130 participants across 1 site.

Detailed Summary

Randomized phase II trial. The study aims to investigate a different and potentially safer radio therapeutic treatment method for brain metastases. The current standard of stereotactic radiotherapy (SRT) in one or three fractions is compared to fractionated stereotactic radiotherapy (fSRT) in five fractions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Metastases
CountriesNetherlands
Collaborators--

Timeline

N/ARecruiting
20232024202520262027
First PostedApr 26, 2022
Enrollment StartJul 18, 2022
Primary CompletionMar 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 4.2 years agoPrimary completion in 8 months

Interventions

SRTradiation

SRT

fSRTradiation

fSRT